A group of China-based investors is backing Bioatla LLC's bid to address growing demand for new immunotherapies in the country with a $30 million equity buy-in. Bioatla President, CEO and Chairman Jay Short called it a "transformative event" that will help the company leverage expertise at its established Beijing lab to build new strategic partnerships with Chinese biophama companies in pursuit of further developing its conditionally active biologic (CAB) antibody platform and other technologies.
SHANGHAI – Inside Johnson & Johnson Innovation Center's 17-deal announcement, the Asia Pacific Innovation Center (APIC) shows it has been busy, too, signing four deals in the region: in Japan, Australia, Mainland China and Taiwan.
HONG KONG & NEW DELHI – Middle East respiratory syndrome (MERS) is in the spotlight across Asia, as researchers search for drugs to fight a virus many fear could be as devastating as SARS was in 2003.
SHANGHAI – New out of the gate, Suzhou Neupharma Co. Ltd., has put its first candidate, RX-108, into clinical trials. Like many companies in China with global ambitions, Neupharma is collecting its first-in-human data in Australia while it waits for its trials to get a green light in China. (See Beigene story this issue.)
LUCKNOW, India – An Indian government-funded drug research institute plans to set up a biopharma industry incubation center to attract entrepreneurs in northern and central India, areas that are home to a number of high-quality research laboratories but are in dire need of bioclusters.
TAIPEI, Taiwan – Pharmaengine Inc. said it submitted a new drug application (NDA) to the TFDA, Taiwan's drug regulatory body, for the liposome version of irinotecan, PEP02, as a second-line treatment for pancreatic cancer patients who have failed gemcitabine therapy.
SHANGHAI – The Beijing-based oncology company Beigene Co. Ltd. continuing its string of upbeat news, announcing the first human dosing of its programmed death-1 (PD-1) antibody, BGB-A317, in Australia.
RSS